STRO-002-GM2: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination with Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sutro Biopharma Inc. published this content on 04 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2022 20:51:04 UTC.